EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients

Phillip Schiele iD, Stefan Kolling iD, Stanislav Rosnev iD, Charlotte Junkuhn iD, Anna Luzie Walter, Jobst Christian von Einem iD, Sebastian Stintzing iD, Wenzel Schöning, Igor Maximilian Sauer iD, Dominik Paul Modest, Kathrin Heinrich, Lena Weiss und 4 weitere

Cells · 2024

DOI: 10.3390/cells14010032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Phillip Schiele und 15 weiteren Autor:innen. Beteiligte Einrichtung: BIH Center for Regenerative Therapies (BCRT), Therapy-Induced Remodeling in Immuno-Oncology, Berlin Institute of Health at Charité-Universitätsmedizi…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Colorectal Neoplasms, Receptors, IgG, Antibody-Dependent Cell Cytotoxicity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Ludwig-Maximilians-Universität München—Klinikum Großhadern, Merck KGaA, Darmstadt, Berlin School of Integrative Oncology (BSIO) Accelerator Award for Emerging Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells is a key mechanism in anti-cancer therapies with monoclonal antibodies, including cetuximab (EGFR-targeting) and avelumab (PDL1-targeting). Fc gamma receptor IIIa (FcγRIIIa) polymorphisms impact ADCC, yet their clinical relevance in NK cell functionality remains debated. We developed two complementary flow cytometry assays: one to predict the FcγRIIIa-V158F polymorphism using a machine learning model, and a 15-color flow cytometry panel to assess antibody-induced NK cell functionality and cancer-immune cell interactions. Samples were collected from healthy donors and metastatic colorectal cancer (mCRC) patients from the FIRE-6-Avelumab phase II study. The machine learning model accurately predicted the FcγRIIIa-V158F polymorphism in 94% of samples. FF homozygous patients showed diminished cetuximab-mediated ADCC compared to VF or VV carriers. In mCRC patients, NK cell dysfunctions were evident as impaired ADCC, decreased CD16 downregulation, and reduced CD137/CD107a induction. Elevated PD1+ NK cell levels, reduced lysis of PDL1-expressing CRC cells and improved NK cell activation in combination with the PDL1-targeting avelumab indicate that the PD1-PDL1 axis contributes to impaired cetuximab-induced NK cell function. Together, these optimized assays effectively identify NK cell dysfunctions in mCRC patients and offer potential for broader application in evaluating NK cell functionality across cancers and therapeutic settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalColorectal NeoplasmsReceptors, IgGAntibody-Dependent Cell CytotoxicityFlow CytometryCetuximabHumansAntibodies, Monoclonal, HumanizedFemaleMalePolymorphism, GeneticMiddle AgedCell Line, Tumor

Stichwörter der Autor:innen

antibody-dependent cell cytotoxicitycetuximabcolorectal neoplasmsflow cytometrynatural killer cellssingle nucleotide polymorphism

Substanzen

Receptors, IgGFCGR3A protein, humanCetuximabAntibodies, Monoclonal, Humanizedavelumab

Autor:innen und Institutionen

  • BIH Center for Regenerative Therapies (BCRT), Therapy-Induced Remodeling in Immuno-Oncology, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
  • Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany.
  • BIH Biomedical Innovation Academy, BIH Charité Junior Digital Clinician Scientist Program, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, 10178 Berlin, Germany.
  • BSIO Berlin School of Integrative Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10178 Berlin, Germany.
  • Medical Department of Hematology, Oncology and Tumor Immunology, Molekulares Krebsforschungszentrum (MKFZ), Charité-Universitätsmedizin, 10117 Berlin, Germany.
  • MVZ Onkologie Tiergarten, 10559 Berlin, Germany.

ORCID-Profile: Phillip Schiele, Stefan Kolling, Stanislav Rosnev, Charlotte Junkuhn, Jobst Christian von Einem, Sebastian Stintzing, Igor Maximilian Sauer, Volker Heinemann, Lars Bullinger

Förderung

  • Klinikum der Ludwig-Maximilians-Universität München—Klinikum Großhadern
  • Merck KGaA, Darmstadt
  • Berlin School of Integrative Oncology (BSIO) Accelerator Award for Emerging Projects
  • Charité—Universitätsmedizin Berlin
  • Berlin Institute of Health at Charité (BIH)

Zitieren

APA

Schiele, P., Kolling, S., Rosnev, S., Junkuhn, C., Walter, A. L., von Einem, J. C., Stintzing, S., Schöning, W., Sauer, I. M., Modest, D. P., Heinrich, K., Weiss, L., Heinemann, V., Bullinger, L., Frentsch, M., & Na, I. K. (2024). Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients. Cells. https://doi.org/10.3390/cells14010032

Vancouver

Schiele P, Kolling S, Rosnev S, Junkuhn C, Walter AL, von Einem JC, et al. Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients. Cells. 2024. doi:10.3390/cells14010032

BibTeX
@article{Schiele2024,
  author = {Schiele, Phillip and Kolling, Stefan and Rosnev, Stanislav and Junkuhn, Charlotte and Walter, Anna Luzie and von Einem, Jobst Christian and Stintzing, Sebastian and Schöning, Wenzel and Sauer, Igor Maximilian and Modest, Dominik Paul and Heinrich, Kathrin and Weiss, Lena and Heinemann, Volker and Bullinger, Lars and Frentsch, Marco and Na, Il-Kang},
  title = {Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells14010032}
}
Kostenlos starten →